Biodesix, Inc. (NASDAQ:BDSX) Given Average Rating of “Moderate Buy” by Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $26.50.

A number of analysts have recently commented on the company. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Canaccord Genuity Group increased their price target on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, June 18th. HC Wainwright assumed coverage on Biodesix in a report on Monday, June 15th. They issued a “buy” rating and a $26.00 price target for the company. William Blair upgraded Biodesix from a “market perform” rating to an “outperform” rating in a report on Friday, February 27th. Finally, Roth Mkm assumed coverage on Biodesix in a report on Wednesday. They issued a “buy” rating for the company.

Biodesix Trading Down 2.6%

Shares of BDSX stock traded down $0.49 on Wednesday, reaching $18.67. 108,608 shares of the stock were exchanged, compared to its average volume of 784,910. The stock has a market cap of $193.35 million, a P/E ratio of -4.60 and a beta of 0.59. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 5.09. The firm has a 50 day moving average of $14.39 and a two-hundred day moving average of $12.43. Biodesix has a 1-year low of $5.01 and a 1-year high of $20.21.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.32. The business had revenue of $25.56 million during the quarter, compared to the consensus estimate of $23.12 million. Biodesix had a negative return on equity of 2,101.40% and a negative net margin of 33.26%. On average, research analysts anticipate that Biodesix will post -2.93 EPS for the current year.

Institutional Trading of Biodesix

Large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC acquired a new stake in shares of Biodesix during the first quarter valued at about $10,996,000. Aberdeen Group plc acquired a new stake in shares of Biodesix during the fourth quarter valued at about $1,784,000. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Biodesix during the first quarter valued at about $1,015,000. Finally, Sei Investments Co. acquired a new stake in shares of Biodesix during the first quarter valued at about $624,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.